Author:
Gao Ke,Zhang Fang,Chen Ke,Li Wei,Guan Yi-Bing,Xu Meng-Lu,Chong Tie,Dai Zhi-Ming
Abstract
AbstractKidney cancer is the third most common malignancy of the urinary system, of which, kidney renal clear cell carcinoma (KIRC) accounts for the vast majority. Runt-related transcription factors (RUNX) are involved in multiple cellular functions. However, the diverse expression patterns and prognostic values of RUNX genes in kidney cancer remained to be elucidated. In our study, we mined the DNA methylation, transcriptional and survival data of RUNX genes in patients with different kinds of kidney cancer through Oncomine, Gene Expression Profiling Interactive Analysis, UALCAN, Kaplan–Meier Plotter, cBioPortal and LinkedOmics. We found that RUNX1 and RUNX3 were upregulated in KIRC tissues compared with those in normal tissues. The survival analysis results indicated a high transcription level of RUNX1 was associated with poor overall survival (OS) in KIRC patients. Furthermore, KIRC tumor tissues had significantly lower levels of RUNX1 promoter methylation than that in paracancerous tissues, with decreased DNA methylation of RUNX1 notably associated with poor OS in KIRC. In conclusion, our results revealed that RUNX1 may be a potential therapeutic target for treating KIRC, and RUNX1 promoter methylation level shows promise as a novel diagnostic and prognostic biomarker, which laid a foundation for further study.
Funder
The Talent Fund Project of the Second Affiliated Hospital of Xi'an Jiaotong University
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Freddie, B. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 68(6), 394–424 (2018).
2. Aristotle, B. et al. Current clinical practice guidelines for the treatment of renal cell carcinoma: A systematic review and critical evaluation. Oncologist 22(6), 667 (2017).
3. Choueiri, T. K. et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 19(4), 451–460 (2018).
4. Wooseok, S. & Ichiro, T. The roles of RUNX family proteins in development of immune cells. Mol. Cells 43(2), 107 (2020).
5. Richiardi, L. et al. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 27(19), 3161–3168 (2009).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献